MAPT and Alzheimer disease: In fact, our results demonstrate that the highly AD specific p-tau residues measured by CSF biomarkers (i.e., p-tau181, p-tau217, p-tau231, and p-tau235) are also highly increased in AD brain compared with controls and non-AD tauopathies, especially in SI fractions.